在健康养生领域方面，本集团拟发展健康养生产业的布局。建议计划包括建立全国性健康养生连锁店网 络、发挥店舖集群优势，并强化整体产业链上下游以形成闭环生态体系。 本集团将积极探索产业链的纵向延伸与横向协作。透过战略投资、业务合作及併购，本集团拟连系医学 美容与健康养生领域的更多伙伴与资源，旨在构建开放、协作、互利互惠的产业生态平台，为两大连锁 产业培育新的增长曲线。 董事局相信，新业务将为本公司股东创造长期价值，并巩固本集团于中国的战略定位。 俊裕地基(01757)发布公告，因应中国民众消费水平提升及人口老化趋势，本集团将积极配合国家政 策，计划于中国开展新业务，重点发展两大连锁产业：(i)医学美容;及(ii)健康养生(新业务)。 在医学美容领域方面，本集团拟集中发展医学美容业务，包括整合全国顶尖医疗专家团队、设立高端医 学美容医院，并与再生医学机构建立合作关係。本集团旨在打造全面且专业的医学美容生态体系。 ...

智通财经APP讯，俊裕地基(01757)发布公告，因应中国民众消费水平提升及人口老化趋势，本集团将积 极配合国家政策，计划于中国开展新业务，重点发展两大连锁产业：(i)医学美容;及(ii)健康养生(新业 务)。 在健康养生领域方面，本集团拟发展健康养生产业的布局。建议计划包括建立全国性健康养生连锁店网 络、发挥店舖集群优势，并强化整体产业链上下游以形成闭环生态体系。 本集团将积极探索产业链的纵向延伸与横向协作。透过战略投资、业务合作及併购，本集团拟连系医学 美容与健康养生领域的更多伙伴与资源，旨在构建开放、协作、互利互惠的产业生态平台，为两大连锁 产业培育新的增长曲线。 在医学美容领域方面，本集团拟集中发展医学美容业务，包括整合全国顶尖医疗专家团队、设立高端医 学美容医院，并与再生医学机构建立合作关係。本集团旨在打造全面且专业的医学美容生态体系。 董事局相信，新业务将为本公司股东创造长期价值，并巩固本集团于中国的战略定位。 ...

格隆汇2月6日丨俊裕地基(01757.HK)公告，因应中国民众消费水平提升及人口老化趋势，集团将积极配 合国家政策，计划于中国开展新业务，重点发展两大连锁产业：(i)医学美容；及(ii)健康养生(「新业 务」)。 在医学美容领域方面，集团拟集中发展医学美容业务，包括整合全国顶尖医疗专家团队、设立高端医学 美容医院，并与再生医学机构建立合作关系。集团旨在打造全面且专业的医学美容生态体系。 在健康养生领域方面，集团拟发展健康养生产业的布局。建议计划包括建立全国性健康养生连锁店网 络、发挥店舖集群优势，并强化整体产业链上下游以形成闭环生态体系。 集团将积极探索产业链的纵向延伸与横向协作。透过战略投资、业务合作及并购，集团拟连系医学美容 与健康养生领域的更多夥伴与资源，旨在构建开放、协作、互利互惠的产业生态平台，为两大连锁产业 培育新的增长曲线。 ...

Core Viewpoint - The article discusses an upcoming investment roadshow organized by the Zhongguancun Alliance for New Biomedical Industry and SiYu MedTech, aimed at connecting investors with projects in the biomedical and medical device sectors [4][6]. Group 1: Event Details - The roadshow will take place on January 29, 2026, at 14:00, both online via Tencent Meeting and in-person at Tsinghua Science Park [4]. - The event is free of charge and serves as a public service for alliance members, with a project vetting process in place [6]. - Projects eligible for participation range from angel to Series C funding stages, covering fields such as biomedicine, medical devices, and medical aesthetics [4][6]. Group 2: Investor Participation - The event will feature a curated list of investors who have relevant investment experience and have been pre-approved [4]. - Post-event, the organizers will facilitate connections between interested investors and project CEOs [4]. Group 3: Participating Investors - A comprehensive list of participating investment institutions includes notable names such as Sequoia Capital, IDG, and various other venture capital firms, ensuring a diverse range of potential funding sources [7].

Core Viewpoint - The article discusses an upcoming investment roadshow organized by the Zhongguancun Alliance for New Biomedical Industry and SiYu MedTech, aimed at connecting investors with projects in the biomedical and medical device sectors [4][6]. Group 1: Event Details - The roadshow will take place on December 25, 2025, at 14:00, both online via Tencent Meeting and in-person at Tsinghua Science Park [4]. - The event is free of charge and serves as a public service for alliance members, with a project vetting process in place to ensure quality participation [6]. Group 2: Target Participants - Projects eligible for the roadshow include those in the financing stages from angel round to Series C, covering fields such as biomedicine, medical devices, and medical aesthetics [4][6]. - Founders of participating projects come from backgrounds in research, medicine, and large enterprises, indicating a strong educational and professional pedigree [4]. Group 3: Investor Participation - A curated list of investors will be invited to the roadshow, including well-known firms such as Sequoia Capital, IDG, and others, ensuring that only qualified institutions with relevant investment experience are involved [7]. - After the roadshow, the organizers will facilitate connections between interested investors and project CEOs [4].

Core Viewpoint - The company has submitted an application for a transfer to the Main Board of the Hong Kong Stock Exchange, which is expected to enhance its corporate image and public recognition without issuing new shares [1] Group 1: Benefits of Main Board Listing - The company believes that the larger market capitalization, higher trading volume, and greater international recognition of the Main Board will significantly improve its corporate image and public recognition [1] - The stricter listing requirements of the Main Board are seen as a strong acknowledgment of the company's operational performance and market position [1] - The enhanced reputation is expected to improve the company's ability to attract and retain high-quality clients, business partners, and talent, while also helping to seize new business opportunities [1] Group 2: Investor Engagement and Financing - The transfer to the Main Board is anticipated to broaden the company's access to a wider range of investors, including institutional and professional investors, as well as international participants, thereby expanding and diversifying its shareholder base [1] - The company expects that the Main Board listing will enhance its financing flexibility, allowing it to obtain more diversified debt financing options under more favorable conditions [1] - This move is projected to support the optimization of the company's capital structure and provide more strategic financial management space [1] Group 3: Long-term Growth and Value Creation - The board believes that the transfer to the Main Board will have a positive impact on the company's sustainable growth and long-term development, thereby consolidating its leading position in the medical beauty sector and creating lasting value for the company and its shareholders [2]

Core Viewpoint - The company has submitted an application for a transfer to the Main Board of the Hong Kong Stock Exchange, which is expected to enhance its corporate image and public recognition without issuing new shares [1] Group 1: Benefits of Main Board Listing - The transfer to the Main Board is anticipated to significantly improve the company's corporate image and public recognition due to the larger market capitalization, higher trading volume, and greater international visibility associated with the Main Board [1] - The stricter listing requirements of the Main Board are seen as a strong recognition of the company's operational performance and market position, which is expected to enhance its ability to attract and retain high-quality clients, business partners, and talent [1] - The listing on the Main Board is expected to broaden the company's access to a wider range of investors, including institutional and international participants, thereby expanding and diversifying its shareholder base [1] Group 2: Financial Flexibility and Growth - The company anticipates that the Main Board listing will enhance its financing flexibility, allowing it to obtain more diversified debt financing options under more favorable conditions [1] - This move is expected to support the optimization of the company's capital structure and provide more strategic financial management space [1] - The board believes that the transfer to the Main Board will have a positive impact on the company's sustainable growth and long-term development, reinforcing its leading position in the medical beauty sector and creating lasting value for the company and its shareholders [2]

Core Viewpoint - The article discusses an upcoming investment roadshow organized by the Zhongguancun Alliance for New Biomedical Industry and SiYu MedTech, aimed at connecting investors with projects in the biomedical and medical device sectors [4]. Group 1: Event Details - The roadshow will take place on December 25, 2025, at 14:00, both online via Tencent Meeting and in-person at Tsinghua Science Park [4]. - The event is free of charge and serves as a public service for alliance members, with a project vetting process in place [6]. Group 2: Participating Projects and Investors - Projects eligible for participation range from angel to Series C funding stages, covering fields such as biomedicine, medical devices, and medical aesthetics [4]. - A list of vetted investment institutions will be notified about the roadshow, including notable names like Sequoia Capital, IDG, and others [7].

Group 1 - The core announcement is that Bright Sunny Holdings (stock code: 8603) plans to raise approximately HKD 50 million through the placement of new shares, issuing 18,920,000 shares at a price of HKD 2.61, which represents a discount of about 17.9% from the previous closing price of HKD 3.18 [1] - The placement shares account for approximately 2.4% of the existing issued share capital and will represent about 2.3% of the enlarged share capital after completion [1] - The funds raised will be used to supplement general working capital, including employee costs, rent expenses, and other business and company expenditures [1] Group 2 - Bright Sunny Holdings primarily provides medical beauty services in Hong Kong, operating medical beauty centers and selling skincare products [1]

Core Points - The article discusses an upcoming investment roadshow organized by the Zhongguancun Lianxin Biomedicine Industry Alliance and Siyu MedTech, scheduled for November 27, 2025, at Tsinghua Science Park [4][6] - The roadshow aims to connect investors with projects in the biomedicine, medical devices, and medical aesthetics sectors, allowing projects from angel to Series C funding stages to participate [4][6] - Participation is free for alliance members, but projects must undergo a review process to be accepted [6] Group 1: Event Details - The roadshow will be held both online via Tencent Meeting and in-person [4] - The event will feature projects led by founders with backgrounds in research, medicine, and large enterprises, ensuring a high level of expertise [4] - A list of vetted investment institutions will be notified about the roadshow, including notable names such as Sequoia Capital and IDG [7] Group 2: Participation Criteria - Projects eligible for the roadshow must be in the financing stages from angel round to Series C [4] - The sectors of interest include biomedicine, medical devices, and medical aesthetics [4] - Interested projects can apply by filling out a registration form linked in the article [5][6]